Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2026-04-16 @ 2:25 PM
Study NCT ID:
NCT02101268
Status:
COMPLETED
Last Update Posted:
2023-05-23
First Post:
2014-03-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Sponsor:
Sierra Oncology LLC - a GSK company
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module